Business, energy, technology, markets and global industry news from Business News Today

pediatric endocrinology

PharmaDeviceNews pediatric endocrinology
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More
Representative image: Pediatric endocrine care is drawing renewed attention as Neurocrine Biosciences’ CRENESSITY two-year CAHtalyst Pediatric data show durable hormone control, reduced glucocorticoid exposure and potential long-term clinical benefits for children with classic congenital adrenal hyperplasia.
Pharma & Biotech

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More